Last reviewed · How we verify
Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with disease recurrence or metastasis — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Aromatase inhibitor | aromatase-inhibitor | Pfizer | Aromatase inhibitor | Aromatase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with disease recurrence or metastasis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with disease recurrence or metastasis:
- Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with disease recurrence or metastasis treatment updates — RSS
- Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with disease recurrence or metastasis treatment updates — Atom
- Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with disease recurrence or metastasis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with disease recurrence or metastasis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/adjuvant-treatment-of-hormone-receptor-positive-breast-cancer-in-postmenopausal-women-with-disease-recurrence-or-metastasis. Accessed 2026-06-10.
Related
- Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with disease recurrence or metastasis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing